Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer
Atossa Therapeutics (NASDAQ: ATOS) announced its participation in a fireside chat at BIO-Europe 2024 in Stockholm, Sweden. The event, scheduled for November 4-6, 2024, will feature Dr. Steven Quay, CEO of Atossa, and Dr. Per Hall from the Karolinska Institute discussing the potential of combining AI-based risk models with emerging therapies to prevent breast cancer in high-risk patients.
The discussion will focus on the Stockholm Mammography Risk Stratified Trial (SMART), a study aiming to enroll 70,000 women to test an individualized, imaging-based screening model. This model is designed to identify women at the highest risk of developing breast cancer within two years. If validated, it could serve as a foundation for future trials investigating (Z)-endoxifen in breast cancer prevention.
Atossa Therapeutics is a clinical-stage biopharmaceutical company developing innovative medicines for oncology, with a focus on breast cancer prevention and treatment using (Z)-endoxifen.
Atossa Therapeutics (NASDAQ: ATOS) ha annunciato la sua partecipazione a un fireside chat al BIO-Europe 2024 a Stoccolma, Svezia. L'evento, in programma dal 4 al 6 novembre 2024, vedrà la partecipazione del Dott. Steven Quay, CEO di Atossa, e del Dott. Per Hall del Karolinska Institute, che discuteranno il potenziale di combinare modelli di rischio basati su AI con nuove terapie per prevenire il cancro al seno in pazienti ad alto rischio.
La discussione verterà sul Stockholm Mammography Risk Stratified Trial (SMART), uno studio che mira a reclutare 70.000 donne per testare un modello di screening personalizzato basato su immagini. Questo modello è progettato per identificare le donne con il rischio più elevato di sviluppare il cancro al seno entro due anni. Se convalidato, potrebbe fungere da base per futuri studi che indagano su (Z)-endoxifene nella prevenzione del cancro al seno.
Atossa Therapeutics è una compagnia biofarmaceutica in fase clinica che sviluppa medicine innovative per l'oncologia, con un focus sulla prevenzione e sul trattamento del cancro al seno utilizzando (Z)-endoxifene.
Atossa Therapeutics (NASDAQ: ATOS) anunció su participación en una charla informal en BIO-Europe 2024 en Estocolmo, Suecia. El evento, programado del 4 al 6 de noviembre de 2024, contará con la presencia del Dr. Steven Quay, CEO de Atossa, y del Dr. Per Hall del Instituto Karolinska, quienes discutirán el potencial de combinar modelos de riesgo basados en IA con terapias emergentes para prevenir el cáncer de mama en pacientes de alto riesgo.
La discusión se centrará en el Stockholm Mammography Risk Stratified Trial (SMART), un estudio que tiene como objetivo inscribir a 70,000 mujeres para probar un modelo de detección personalizado basado en imágenes. Este modelo está diseñado para identificar a las mujeres con el mayor riesgo de desarrollar cáncer de mama en un plazo de dos años. Si se valida, podría servir de base para futuros ensayos que investiguen (Z)-endoxifeno en la prevención del cáncer de mama.
Atossa Therapeutics es una compañía biofarmacéutica en etapa clínica que desarrolla medicamentos innovadores para la oncología, centrándose en la prevención y tratamiento del cáncer de mama utilizando (Z)-endoxifeno.
Atossa Therapeutics (NASDAQ: ATOS)는 스웨덴 스톡홀름에서 열리는 BIO-Europe 2024의 화상 대화에 참여한다고 발표했습니다. 2024년 11월 4일부터 6일까지 예정된 이 행사에는 스티븐 쿼이 박사 (Atossa CEO)와 카롤린스카 연구소의 페르 홀 박사가 참석하여 AI 기반 리스크 모델과 신흥 치료법을 결합하여 고위험 환자의 유방암 예방 가능성에 대해 논의할 예정입니다.
논의는 스톡홀름 유방촬영 리스크 계층화 시험 (SMART)에 초점을 맞추며, 이는 70,000명의 여성을 등록하여 개인화된 이미징 기반 스크리닝 모델을 테스트하는 연구입니다. 이 모델은 향후 2년 내에 유방암 발생 위험이 가장 높은 여성을 식별하도록 설계되었습니다. 검증될 경우, 이는 유방암 예방을 위한 (Z)-엔독시펜을 조사하는 미래 시험의 기초가 될 수 있습니다.
Atossa Therapeutics는 유방암 예방 및 치료에 초점을 맞춘 혁신적인 의약품을 개발하는 임상 단계의 생물제약 회사입니다, (Z)-엔독시펜을 사용하여.
Atossa Therapeutics (NASDAQ: ATOS) a annoncé sa participation à une discussion informelle lors de BIO-Europe 2024 à Stockholm, Suède. Cet événement, prévu du 4 au 6 novembre 2024, mettra en vedette Dr. Steven Quay, PDG d'Atossa, et Dr. Per Hall de l'Institut Karolinska, qui discuteront du potentiel de la combinaison des modèles de risque basés sur l'IA avec des thérapies émergentes pour prévenir le cancer du sein chez les patientes à haut risque.
La discussion se concentrera sur le Stockholm Mammography Risk Stratified Trial (SMART), une étude visant à recruter 70 000 femmes pour tester un modèle de dépistage individualisé basé sur l'imagerie. Ce modèle est conçu pour identifier les femmes présentant le risque le plus élevé de développer un cancer du sein dans les deux ans. Si validé, il pourrait servir de base à de futurs essais examinant (Z)-endoxifène dans la prévention du cancer du sein.
Atossa Therapeutics est une entreprise bio-pharmaceutique en phase clinique développant des médicaments innovants pour l'oncologie, avec un accent sur la prévention et le traitement du cancer du sein en utilisant (Z)-endoxifène.
Atossa Therapeutics (NASDAQ: ATOS) gab bekannt, an einer Fireside-Chat-Veranstaltung auf dem BIO-Europe 2024 in Stockholm, Schweden, teilzunehmen. Die Veranstaltung, die vom 4. bis 6. November 2024 stattfindet, wird Dr. Steven Quay, CEO von Atossa, und Dr. Per Hall vom Karolinska Institut umfassen, die über das Potenzial der Kombination von KI-basierten Risikomodellen mit neuen Therapien zur Prävention von Brustkrebs bei Hochrisikopatienten diskutieren werden.
Die Diskussion wird sich auf die Stockholm Mammography Risk Stratified Trial (SMART) konzentrieren, eine Studie, die darauf abzielt, 70.000 Frauen zu rekrutieren, um ein individualisiertes, bildgestütztes Screening-Modell zu testen. Dieses Modell soll Frauen mit dem höchsten Risiko, innerhalb von zwei Jahren Brustkrebs zu entwickeln, identifizieren. Wenn es validiert wird, könnte es als Grundlage für zukünftige Studien zur Untersuchung von (Z)-Endoxifen zur Brustkrebsprävention dienen.
Atossa Therapeutics ist ein biopharmazeutisches Unternehmen in der klinischen Phase, das innovative Medikamente für die Onkologie entwickelt, mit einem Schwerpunkt auf der Prävention und Behandlung von Brustkrebs unter Verwendung von (Z)-Endoxifen.
- None.
- None.
SEATTLE, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) (“Atossa” or the “Company”), today announced that Steven Quay, M.D., Ph.D., Chairman and Chief Executive Officer, will join Per Hall, M.D., Professor of Epidemiology at the Department of Medical Epidemiology and Biostatistics at Karolinska Institute, at a fireside chat at BIO-Europe 2024. During the fireside chat, Drs. Quay and Hall will discuss a meaningful approach to combining a state-of-the-art, artificial intelligence (AI)-based risk model with promising emerging therapies that may help prevent breast cancer in high-risk patients. BIO-Europe 2024 is scheduled for November 4-6, 2024, in Stockholm, Sweden. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
“I am honored to join Dr. Hall of the Karolinska Institute at BIO-Europe 2024 and discuss the potential for AI and endoxifen to transform the breast cancer treatment paradigm by identifying women at high risk of developing breast cancer who could potentially benefit from treatment to prevent the disease before it develops,” said Steven Quay, M.D., Ph.D. “The focal point of the fireside chat will be the Stockholm Mammography Risk Stratified Trial or SMART study, which Dr. Hall’s laboratory is leading and Atossa is supporting. This groundbreaking study is seeking to enroll 70,000 women to test an individualized, imaging-based screening model designed to identify women with the highest risk of developing breast cancer in the next two years. If the model is validated for therapeutic use, it could serve as the foundation for a future trial investigating (Z)-endoxifen in the breast cancer prevention setting.”
Details of the fireside chat are as follows:
| Event: | BIO-Europe 2024 |
| Fireside Chat: | Atossa Therapeutics and the Karolinska Institute: The SMART study: A Unique Swedish American Collaboration to Prevent Breast Cancer |
| Date and Time | Monday, November 4th at 5:00 PM, CET |
| Location | Room K11, Stockholmsmässan |
About Atossa Therapeutics
Atossa Therapeutics, Inc. (NASDAQ: ATOS) is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. For more information, please visit www.atossatherapeutics.com.
FORWARD LOOKING STATEMENTS
This press release contains certain information that may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We may identify these forward-looking statements by the use of words such as “expect,” “potential,” “continue,” “may,” “will,” “should,” “could,” “would,” “seek,” “intend,” “plan,” “estimate,” “anticipate,” “believe,” “future,” or other comparable words. Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results, outcomes, or the timing of actual results or outcomes, such as data related to the (Z)-endoxifen program, the potential of (Z)-endoxifen as a breast cancer prevention and treatment agent, and potential milestones and growth opportunities for the Company, to differ materially from those projected or anticipated, including risks and uncertainties associated with: macroeconomic conditions and increasing geopolitical instability; the expected timing of releasing data; any variation between interim and final clinical results; actions and inactions by the FDA and foreign regulatory bodies; the outcome or timing of regulatory approvals needed by Atossa, including those needed to continue our planned (Z)-endoxifen trials; our ability to satisfy regulatory requirements; our ability to remain compliant with the continued listing requirements of the Nasdaq Stock Market; our ability to successfully develop and commercialize new therapeutics; the success, costs and timing of our development activities, including our ability to successfully initiate or complete our clinical trials, including our (Z)-endoxifen trials; our anticipated rate of patient enrollment; our ability to contract with third-parties and their ability to perform adequately; our estimates on the size and characteristics of our potential markets; our ability to successfully defend litigation and other similar complaints and to establish and maintain intellectual property rights covering our products; whether we can successfully complete our clinical trial of oral (Z)-endoxifen in women with mammographic breast density and our trials of (Z)-endoxifen in women with breast cancer, and whether the studies will meet their objectives; our expectations as to future financial performance, expense levels and capital sources, including our ability to raise capital; our ability to attract and retain key personnel; our anticipated working capital needs and expectations around the sufficiency of our cash reserves; and other risks and uncertainties detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its Annual Reports on Form 10-K and Quarterly Reports on 10-Q. Forward-looking statements are presented as of the date of this press release. Except as required by law, we do not intend to update any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.
Contact:
Michael Parks
VP, Investor and Public Relations
484-356-7105
michael.parks@atossainc.com
FAQ
What is the main focus of Atossa Therapeutics' fireside chat at BIO-Europe 2024?
Who are the key participants in the Atossa Therapeutics fireside chat at BIO-Europe 2024?
What is the SMART study mentioned in the Atossa Therapeutics press release?
How might the SMART study impact future breast cancer prevention trials for Atossa Therapeutics (ATOS)?
When and where will the Atossa Therapeutics fireside chat take place at BIO-Europe 2024?
